Search Results

There are 3067 results for: content related to: Efficacy, Safety, and Tolerability of Extended-Release Once-Daily Tolterodine Treatment for Overactive Bladder in Older versus Younger Patients

  1. Which anticholinergic drug for overactive bladder symptoms in adults

    Intervention Review

    The Cochrane Library

    Priya Madhuvrata, June D Cody, Gaye Ellis, G Peter Herbison and E. Jean C Hay-Smith

    Published Online : 18 JAN 2012, DOI: 10.1002/14651858.CD005429.pub2

  2. You have free access to this content
    Fluoxetine inhibits the metabolism of tolterodine—pharmacokinetic implications and proposed clinical relevance

    British Journal of Clinical Pharmacology

    Volume 48, Issue 4, October 1999, Pages: 553–563, Brynne, Svanström, Åberg-Wistedt, Hallén and Bertilsson

    Version of Record online : 24 DEC 2001, DOI: 10.1046/j.1365-2125.1999.00051.x

  3. You have free access to this content
    Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial

    BJU International

    Volume 107, Issue 9, May 2011, Pages: 1432–1440, Steven A. Kaplan, Tim Schneider, Jenelle E. Foote, Zhonghong Guan, Martin Carlsson and Jason Gong

    Version of Record online : 21 SEP 2010, DOI: 10.1111/j.1464-410X.2010.09640.x

  4. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review

    International Journal of Clinical Practice

    Volume 65, Issue 4, April 2011, Pages: 487–507, S. A. Kaplan, C. G. Roehrborn, P. Abrams, C. R. Chapple, T. Bavendam and Z. Guan

    Version of Record online : 7 JAN 2011, DOI: 10.1111/j.1742-1241.2010.02611.x

  5. You have free access to this content
    Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity

    British Journal of Clinical Pharmacology

    Volume 48, Issue 4, October 1999, Pages: 564–572, Brynne, Forslund, Hallén, Gustafsson and Bertilsson

    Version of Record online : 24 DEC 2001, DOI: 10.1046/j.1365-2125.1999.00053.x

  6. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature

    International Journal of Clinical Practice

    Volume 65, Issue 5, May 2011, Pages: 567–585, C. C. Sexton, S. M. Notte, C. Maroulis, R. R. Dmochowski, L. Cardozo, D. Subramanian and K. S. Coyne

    Version of Record online : 13 APR 2011, DOI: 10.1111/j.1742-1241.2010.02626.x

  7. You have free access to this content
    Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers

    British Journal of Clinical Pharmacology

    Volume 72, Issue 2, August 2011, Pages: 226–234, Bimal Malhotra, Edress Darsey, Penelope Crownover, Juanzhi Fang and Paul Glue

    Version of Record online : 11 JUL 2011, DOI: 10.1111/j.1365-2125.2011.03948.x

  8. You have free access to this content
    Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration

    BJU International

    Volume 106, Issue 9, November 2010, Pages: 1332–1338, Christopher R. Chapple, Sender Herschorn, Paul Abrams, Joseph T. Wang, Marina Brodsky and Zhonghong Guan

    Version of Record online : 24 MAY 2010, DOI: 10.1111/j.1464-410X.2010.09359.x

  9. Clinical safety, tolerability and efficacy of combination tolterodine/pilocarpine in patients with overactive bladder

    International Journal of Clinical Practice

    Volume 68, Issue 8, August 2014, Pages: 986–994, R. R. Dmochowski, D. R. Staskin, K. Duchin, M. Paborji and T. M. Tremblay

    Version of Record online : 25 MAR 2014, DOI: 10.1111/ijcp.12409

  10. Electrochemical Oxidation of Tolterodine

    Electroanalysis

    Volume 25, Issue 1, January 2013, Pages: 205–212, Pavla Macíková, Jana Skopalová, Petr Cankař, Barbora Papoušková, Radka Straková, David Jirovský and Vítězslav Maier

    Version of Record online : 2 OCT 2012, DOI: 10.1002/elan.201200388

  11. You have free access to this content
    Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β3-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction

    BJU International

    Volume 110, Issue 2b, July 2012, Pages: E132–E142, James I. Gillespie, Stefano Palea, Veronique Guilloteau, Marc Guerard, Philippe Lluel and Cees Korstanje

    Version of Record online : 27 JUN 2012, DOI: 10.1111/j.1464-410X.2012.11240.x

  12. Thorough QT Study with Recommended and Supratherapeutic Doses of Tolterodine

    Clinical Pharmacology & Therapeutics

    Volume 81, Issue 3, March 2007, Pages: 377–385, B K Malhotra, P Glue, K Sweeney, R Anziano, J Mancuso and P Wicker

    Version of Record online : 26 FEB 2007, DOI: 10.1038/sj.clpt.6100089

  13. You have free access to this content
    Gender specificity of tolterodine on micturition and the diurnal variation of urine production of the conscious rat

    BJU International

    Volume 86, Issue 7, November 2000, Pages: 879–885, Y. Yoshimura, F. Schmidt and C.E. Constantinou

    Version of Record online : 24 DEC 2001, DOI: 10.1046/j.1464-410x.2000.00890.x

  14. You have free access to this content
    Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial

    BJU International

    Volume 105, Issue 1, January 2010, Pages: 58–66, Sender Herschorn, Steven Swift, Zhonghong Guan, Martin Carlsson, Jon D. Morrow, Marina Brodsky and Jason Gong

    Version of Record online : 16 DEC 2009, DOI: 10.1111/j.1464-410X.2009.09086.x

  15. You have free access to this content
    Effects on bladder function of combining elocalcitol and tolterodine in rats with outflow obstruction

    BJU International

    Volume 110, Issue 2b, July 2012, Pages: E125–E131, Tomi Streng, Karl-Erik Andersson, Petter Hedlund, Christian Gratzke, Enrico Baroni, Daniele D'Ambrosio and Fabio Benigni

    Version of Record online : 30 JAN 2012, DOI: 10.1111/j.1464-410X.2011.10838.x

  16. Effect of the Proton Pump Inhibitor Omeprazole on the Pharmacokinetics of Extended-Release Formulations of Oxybutynin and Tolterodine

    The Journal of Clinical Pharmacology

    Volume 45, Issue 8, August 2005, Pages: 961–968, Roger Dmochowski, Andrew Chen, Gayatri Sathyan, Scott MacDiarmid, Shalini Gidwani and Suneel Gupta

    Version of Record online : 19 MAR 2013, DOI: 10.1177/0091270005278055

  17. You have free access to this content
    Tolterodine and its Active 5-Hydroxymethyl Metabolite: Pure Muscarinic Receptor Antagonists

    Pharmacology & Toxicology

    Volume 90, Issue 5, May 2002, Pages: 260–267, Lisbeth Nilvebrant

    Version of Record online : 18 JUN 2002, DOI: 10.1034/j.1600-0773.2002.900506.x

  18. You have free access to this content
    The use of tolterodine in children after oxybutynin failure

    BJU International

    Volume 91, Issue 4, March 2003, Pages: 398–401, S. Bolduc, J. Upadhyay, J. Payton, D.J. Bägli, G.A. McLorie, A.E. Khoury and W. Farhat

    Version of Record online : 30 JUL 2009, DOI: 10.1046/j.1464-410X.2003.04085.x

  19. You have free access to this content
    The overactive bladder in children: a potential future indication for tolterodine

    BJU International

    Volume 87, Issue 6, April 2001, Pages: 569–574, K. Hjälmås, A-L. Hellström, K. Mogren, G. Läckgren and A. Stenberg

    Version of Record online : 12 JAN 2002, DOI: 10.1046/j.1464-410X.2001.00084.x

  20. Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder

    Neurourology and Urodynamics

    Volume 30, Issue 1, January 2011, Pages: 75–82, Josef Marencak, Nandini H. Cossons, Amanda Darekar and Ian W. Mills

    Version of Record online : 30 SEP 2010, DOI: 10.1002/nau.20928